Home/Pipeline/NCP-based Combination Therapy

NCP-based Combination Therapy

Solid Tumors

Pre-clinicalActive

Key Facts

Indication

Solid Tumors

Phase

Pre-clinical

Status

Active

Company

Coordination Pharmaceuticals

About Coordination Pharmaceuticals

Coordination Pharmaceuticals is an early-stage biotech leveraging a novel nanotechnology platform, Nanoscale Coordination Polymers (NCPs), to create targeted combination therapies for cancer. Founded on research from Professor Wenbin Lin's lab at the University of Chicago, the company focuses on overcoming the limitations of current immuno-oncology treatments by increasing drug delivery to tumors and enhancing T-cell infiltration. As a private, pre-revenue company, its primary goal is to advance its platform through preclinical and clinical development to address unmet needs in solid tumor cancers. Its strategic value lies in the versatility of its NCP platform for co-delivering disparate drug payloads.

View full company profile

Therapeutic Areas

Oncology

Other Solid Tumors Drugs

Drug	Company	Phase	Status
APVO603	Aptevo Therapeutics	Preclinical	Active
APVO711	Aptevo Therapeutics	Preclinical	Active
Platform-derived Immunotherapy	GenCirq	Pre-clinical	Active
DM001	Domabio	Phase 1	Active (IND cleared in US and China)
DM002	Domabio	Phase 1	Active (IND cleared in US)
DM005	Domabio	Phase 1	Active (IND cleared in US, Australia, and China; first patient dosed in US)
SP-2-225	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
SP-1-161	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
CAR-T Solid Tumor Program	Carina Biotech	Phase 1/2a	Active
HBM1020	Harbour BioMed	Phase 1	Active (Global)
HBM7022	Harbour BioMed	Phase 1	Out-Licensed
HBM9033	Harbour BioMed	Discovery	Out-Licensed